Product news

Share this article:

Novartis' Tasigna (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec (imatinib).

Warner Chilcott Company and Watson Pharmaceuticals announced that under a supply agreement Watson has launched Tilia (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the generic version of Warner Chilcott's oral contraceptive Estrostep. Under the terms of the agreement, Warner Chilcott will supply Tilia to Watson Pharma, which will market, sell and distribute the generic product in the US. Warner Chilcott will receive a share of the profits from Watson's sales of the generic product in the US market. Further details on
the agreement have not been disclosed.

Johnson & Johnson submitted a NDA to the FDA for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular injection, for the treatment of schizophrenia and the prevention of recurrence of the symptoms of schizophrenia.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.